Merck, GSK, J&J Embrace Targeted Sequencing for Drug Development and Biomarker Studies
August 10, 2010
Merck, GSK, J&J Embrace Targeted Sequencing for Drug Development and Biomarker Studies
Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Mayo Clinic Assesses Target-Capture Options as Step Toward Sequencing-Based Molecular Diagnostics
July 13, 2010 / In Sequence - Next-Gen Sequencing Makes Inroads into Clinical Applications in 2010
January 4, 2011 / In Sequence - Exome Sequencing IDs Druggable BRAF Mutation in 47 HCL Patients
June 15, 2011 / Clinical Sequencing News - BGI's Sequencing Projects Tackle Genetic Roots of Cancer and Disease, Reference Organism Assembly
March 22, 2011 / In Sequence - Combination of Sequencing Techniques IDs Potential Tumor Suppressor Genes
December 7, 2010 / In Sequence